RxDoctor Payments Data

Nia Valentine, NP

Family · Pasadena, MDNPI 1518196153

Payments from drug & device makers

$8,256in general payments, 2019–2025

Across 441 payments — averaging $18.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Abbott$892
  • Collegium Pharmaceutical, Inc.$831
  • Nevro Corp.$577
  • Vertos Medical, Inc.$540
  • Scilex Pharmaceuticals Inc.$508
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$8,256100%
  • Gifts$00%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,256 in reported general payments places this provider in the 95th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$49,909
Medicare patients
230
Services billed
534

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl14$12,635
MovantikNaloxegol Oxalate16$6,319
Oxycodone Hcl367$5,087
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen182$4,206
Pregabalin148$4,045
Lidocaine35$3,887
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen112$2,337
Gabapentin160$2,091
Cyclobenzaprine Hcl140$1,682
Tizanidine Hcl136$1,243
Morphine Sulfate ErMorphine Sulfate66$905
Diclofenac Sodium30$847
Fentanyl14$660
Meloxicam74$483
Tramadol Hcl60$444

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca$831$12,63514 claims
Redhill Biopharma Inc.Movantik$72$6,31916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,843 family providers in Maryland.

Other family in Pasadena

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →